ASH News Daily - Saturday, December 10, 2011 - (Page B-8)

Page B–8 ® ASH NewS DAily Saturday, December 10, 2011 career-development awardS MMSAP Helps Many Plan for a Future in Hematology he Minority Medical Student Award Program (MMSAP) encourages minority medical students to pursue an interest in hematology research. For an eight- to 12-week period, MMSAP participants work closely with their mentors on a hematology-related research project. The research topics investigated by this year’s students include Waldenström macroglobulinemia, sickle cell anemia, CLL disease progression, and refractory anemia. MMSAP participant Lilian Msambichaka explains, “I hope that the end of the MMSAP program will only be a beginning for future opportunities to expand my work on understanding sickle cell disease.” The awardees will have the opportunity to present their results at the Promoting Minorities in Hematology Reception taking place tonight. Each award recipient also receives the support of a research mentor and a career-development T mentor, a travel stipend to attend the annual meeting, and subscriptions to The Hematologist and Blood. When asked why he was interested in the program, Christopher Rombaoa replied, “I had always been interested in this career path; I defiSecond-Year Participant Steven Ovu Texas A&M Health Science Center – College of Medicine Research Mentor: Gladstone E. Airewele, MD, Baylor College of Medicine Career-Development Mentor: Arthur Steven Ovu W. Bracey Jr., MD, St. Luke Episcopal Hospital Research Project: Study of clinical practice guidelines for the prevention and treatment of acute chest syndrome in sickle cell disease nitely felt the need for more exposure. The prospect of conducting research under the guidance of quality mentors has been an invaluable resource in both planning for a future in hematology as well as navigating the numerous obFirst-Year Participants stacles of medical school. I believe that this program will have a substantial and lasting effect on my career long after I have completed my summer project.” The 2011 MMSAP award recipients are: Maura R. Munoz Ryanne Brown The Ohio State Baylor College University of Medicine Research MenResearch tor: Michael A. Mentor: Miguel Caligiuri, MD, The Cruz, PhD, Ohio State UniverBaylor College sity of Medicine Career-DevelCareerRyanne Brown opment Mentor: Maura R. Munoz Development Belinda R. Avalos, Mentor: Russell MD, The Ohio E. Ware, MD, PhD, Baylor College State University Hospital of Medicine Research Project: In vitro studies Research Project: Characterization of a new bortezomib formulation of the VWF-GPIbα binding-initiated against acute myeloid leukemia »» MMSAP Page B-22 Now Recruiting... A New Clinical Trial for Patients With Multicentric Castleman’s Disease About Multicentric Castleman’s Disease (MCD) MCD is a rare disorder characterized by abnormal noncancerous growths in the lymphatic tissues at multiple sites throughout the body and by systemic manifestations such as fever, night sweats, fatigue, anorexia, and wasting. Also known as giant lymph node hyperplasia or angiofollicular lymph node hyperplasia, MCD can also be misdiagnosed as malignant lymphoma. There is no currently approved treatment for MCD. Study Design 78 Total patients (2:1) Study Overview Ortho Biotech Oncology Research and Development, a unit of Centocor Research and Development, Inc., is conducting a pivotal registration study on MCD. Receive investigational treatment + BSC every 3 weeks Receive placebo + BSC every 3 weeks Primary Objective The primary objective of this study is to demonstrate that an investigational medicine plus best supportive care (BSC) is better than placebo plus BSC in patients with symptomatic MCD. About the Investigational Medicine The investigational medicine is a chimeric monoclonal antibody that blocks the function of the cytokine IL-6. Patients who do not respond to placebo + BSC may be switched to the investigational treatment + BSC The Castleman’s Study www.CastlemansResearch.com CNTO-MCD-ENG14 10 Nov 2009 The Castleman’s Study is being conducted in approximately 24 countries worldwide. As this trial presents a unique opportunity for patients with MCD, you may wish to consider referring your patients with this condition. To find out more, please visit www.CastlemansResearch.com 

Table of Contents for the Digital Edition of ASH News Daily - Saturday, December 10, 2011

ASH News Daily - Saturday, December 10, 2011

https://www.nxtbookmedia.com